where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
Published 7 years ago • 114 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
3:35
is there a use for anti-pdl-1 antibodies in recurrent head and neck cancer?
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
0:39
predicting responses to immunotherapy in head and neck cancer
-
2:14
innovative approaches to the treatment of head and neck cancer
-
26:30
head and neck cancer treatment update: pembrolizumab, nivolumab and pd-l1 markers
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
2:08
future directions for head and neck cancer
-
51:23
a novel approach to the treatment of iga nephropathy
-
7:38
pembrolizumab shows promising activity against head and neck cancer
-
7:56
keynote-048: progression post next line for r/m hnscc
-
1:00
dr. ferris on pembrolizumab and nivolumab in head and neck cancer
-
11:47
pembrolizumab in hnscc
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
6:17
pembrolizumab for head and neck cancer
-
1:58
dr. vokes on nivolumab, pembrolizumab approvals in head and neck cancer
-
5:34
pembrolizumab for recurrent hnscc
-
4:06
immunotherapy for head and neck cancer treatment
-
1:20
resistance to immune checkpoint blockade in patients with cscc
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect